Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion ; volume:13 ; number:1 ; day:25 ; month:3 ; year:2024 ; pages:1-4 ; date:12.2024
Experimental hematology & oncology ; 13, Heft 1 (25.3.2024), 1-4, 12.2024
- Creator
-
Malarikova, Diana
Jorda, Radek
Kupcova, Kristyna
Senavova, Jana
Dolnikova, Alexandra
Pokorna, Eva
Kazantsev, Dmitry
Nozickova, Kristina
Sovilj, Dana
Bellanger, Celine
Chiron, David
Andera, Ladislav
Krystof, Vladimir
Strnad, Miroslav
Helman, Karel
Klanova, Magdalena
Trneny, Marek
Havranek, Ondrej
Klener, Pavel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-024-00499-2
- URN
-
urn:nbn:de:101:1-2405271055436.901662710220
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Malarikova, Diana
- Jorda, Radek
- Kupcova, Kristyna
- Senavova, Jana
- Dolnikova, Alexandra
- Pokorna, Eva
- Kazantsev, Dmitry
- Nozickova, Kristina
- Sovilj, Dana
- Bellanger, Celine
- Chiron, David
- Andera, Ladislav
- Krystof, Vladimir
- Strnad, Miroslav
- Helman, Karel
- Klanova, Magdalena
- Trneny, Marek
- Havranek, Ondrej
- Klener, Pavel
- SpringerLink (Online service)
Other Objects (12)
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Computational study on novel natural inhibitors targeting BCL2
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Computational study on novel natural inhibitors targeting BCL2
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Computational study on novel natural inhibitors targeting BCL2
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors